New drug

New drug
VSY Biotechnology GmbH has announced that a new drug named TR-C 19 has been developed to treat COVID-19 by the company’s research centre. Studies have shown that TR-C 19 can neutralise the virus isolated under laboratory conditions, according to VSY. The drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial. “[This] is one of the most meaningful projects that we have been developing,” said Dr Ercan Varlibas, Chairman of the Board of Directors of VSY Biotechnology GmbH. https://www.vsybiotechnology.com/
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...